Live tape
Top 8, mentions 7d15,603MSFT3,079 mentions▲ +0.09GOOGL2,153 mentions▲ +0.05AAPL2,110 mentions▲ +0.07META2,079 mentions▲ +0.04SNDK1,825 mentions▲ +0.06NVDA1,592 mentions▲ +0.07SPCX1,543 mentions▲ +0.06QQQ1,222 mentions▲ +0.04

Equity · Healthcare

DBVT

DBV Technologies S.A. · NasdaqCM

$13.72 −1.08% 1D Finazon · prior-day close · Jul 24, 2026
Price · Chart Chart by TradingView
Track this symbol on TradingView

The chart above plots the price of DBVT over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 60 sessions over that window: $19.48 on 4 May 2026 through $13.72 on 24 July 2026. Finazon · prior-day close.

Market cap $4.1B
52-week range $8.51 – $28.00
Avg volume 48.8K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Jul 29, 2026

DBVT insider trades

SEC Form 4

DBVT has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 29 January 2026.

Date Insider Type Shares Value
29 Jan 2026 Mohideen Pharis Chief Medical Officer Sell 534 $3K
21 Nov 2025 Mohideen Pharis Chief Medical Officer Sell 1,624 $4K
20 Nov 2025 Mohideen Pharis Chief Medical Officer Sell 6,496 $19K
29 Jul 2025 Mohideen Pharis Chief Medical Officer Sell 464 $1K
Compensation mechanics (4 filings)

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
21 Nov 2025 Tasse Daniel CHIEF EXECUTIVE OFFICER Award 964,000
21 Nov 2025 Boucinha Virginie Chief Financial Officer Award 224,000
21 Nov 2025 Trapp Kevin Michael Chief Commercial Officer Award 371,250
21 Nov 2025 Mohideen Pharis Chief Medical Officer Award 297,000

DBVT reported financials

SEC EDGAR XBRL

DBVT reported revenue of $5.6M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$146.9M.

Figure Reported Period
Revenue $5.6M 31 Dec 2025 fiscal year
Net income −$146.9M 31 Dec 2025 fiscal year
Diluted EPS −$1.05 31 Dec 2025 fiscal year
Total assets $223.2M 30 Jun 2026 at period end
Total equity $160.4M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

DBVT earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.12 $1M
31 Mar 2026 Q1 2026 $-0.11 $1M
31 Dec 2025 FY 2025 $-1.05 $6M
30 Sep 2025 Q3 2025 $-0.24 $3M

Reported figures & scheduled dates · SEC EDGAR filings

DBVT institutional holders

SEC Form 13F

4 of the 45 institutional funds we track reported a DBVT position for the quarter ended 31 Mar 2026 — a combined $50.1M; the latest of those filings landed 15 May 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 1,461,425 $30.5M
Duquesne Family Office New position 383,363 $8.0M
Millennium Management Trimmed −50.2% shares 318,959 $6.7M
Balyasny Asset Management Held (±25%) −0.7% shares 233,429 $4.9M
Citadel Advisors Exited
Marshall Wace Exited
Two Sigma Investments Exited

Source: SEC EDGAR 13F filings

DBVT fails-to-deliver

SEC CNS data

On 25 Jun 2026, 1,910 shares of DBVT failed to deliver (about $30K) — the latest of 4 consecutive trading days with recorded fails.

Settlement date Shares failed Notional % of shares out
25 Jun 2026 1,910 $30K 0.001%
24 Jun 2026 11,605 $187K 0.004%
23 Jun 2026 7,057 $111K 0.002%
22 Jun 2026 262 $4K <0.001%
16 Jun 2026 785 $14K <0.001%

Source: SEC fails-to-deliver (CNS) data